A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Table of Contents We will require substantial funds to maintain our research and development program and support operations in the near term. We have incurred losses and negative cash flows from operations since our inception. As of December 31, 2024, we had $20.0 million in cash and cash equivalents. In March 2025, we completed a registered direct offering and concurrent private placement for net proceeds of approximately $9.0 million. We expect these available cash resources, together with the proceeds from the March 2025 offering, to fund our existing operations into the fourth quarter of 2025. We have based this assessment on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. We will require substantial additional funding in the immediate term to fund the development of emavusertib through regulatory approval and commercialization, and to support our continued operations.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 12M | - | - | - | - | - |
| Net Income | -37M | -43M | -47M | -57M | -45M | -30M |
| EPS | $-3.30 | $-6.88 | $-8.96 | $-12.14 | $0.50 | $-0.61 |
| Free Cash Flow | 0 | -40M | -38M | -55M | -38M | -26M |
| ROIC | -98.1% | -85.3% | -168.3% | -119.4% | -40.8% | -61.5% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | -4.27 | 1.44 | 0.10 | 0.07 | 0.06 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -34M | -45M | -48M | -53M | -42M | -25M |
| Operating Margin | -294.6% | - | - | - | - | - |
| ROE | 0.0% | -634.7% | -241.0% | -121.7% | -41.0% | -61.8% |
| Shares Outstanding | 13M | 6M | 5M | 5M | 92M | 49M |
CURIS INC passes 2 of 9 quality checks, indicating weak fundamentals.
At current prices, the estimated annualized return to fair value is +33.8%.
CURIS INC (CRIS) has a 5-year average return on invested capital (ROIC) of -95.0%. This is below average and may indicate limited pricing power.
CURIS INC (CRIS) has a market capitalization of $8M. It is classified as a small-cap stock.
CURIS INC (CRIS) does not currently pay a regular dividend.
CURIS INC (CRIS) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
CURIS INC (CRIS) generated $-40 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
CURIS INC (CRIS) reported earnings per share (EPS) of $-6.88 in its most recent fiscal year.
CURIS INC (CRIS) has a return on equity (ROE) of -634.7%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 16 years of financial data for CURIS INC (CRIS), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
CURIS INC (CRIS) has a book value per share of $-0.95, based on its most recent annual SEC filing.